Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to the front page

From X

@convequity

Convequity on X

Anthropic's biggest near-term threat isn't the S-1 or AI-safety language. It's competition, especially an OpenAI price war. The S-1 is public, and the timing lines up with OpenAI DevDay. My read is that it isn't a coincidence. That's my read, not something either company has said. What surprised me more came out of DevDay: OpenAI is ending its price war. Here's what that means in practice. OpenAI removed the Pro 20x subscription at $200/month and plans to cut usable tokens on that $200 plan by about half. The allowance was also more generous than it looked. Over the past quarter, OpenAI did roughly 2.5 manual usage resets per week. So heavy users didn't only get a big allowance. It got refilled before they hit the wall, over and over, for about three months. That's a price war fought in tokens instead of list prices, and it is expensive to fund. Why it mattered for Anthropic: for heavy users, cheaper tokens beat a better model. Once a model is good enough, what limits you is how much work you can push through it per dollar. A better model you have to ration loses to a good-enough model you can run all day. Anthropic went the other way and raised margin. That's the right posture for an S-1. It's the wrong posture when a competitor is paying for volume. That left Anthropic in a trap going into the IPO: - Match the pricing, and margin thins just when margin is the story you're selling. - Hold the line, and growth slows as heavy users drift to wherever tokens are cheapest. Either way the numbers get worse at the worst possible time. Ending the price war takes that trap off the table for now. Anthropic gets a cleaner tape into the IPO. Why did OpenAI stop after one quarter? I see two reads, and both are mine, not confirmed: 1. The burn. My read is that OpenAI postponed its own IPO because of how much it was burning, and investors pushed it to stop. 2. OpenAI's own later IPO. If it wants to list, its numbers have to look like a business too. One quarter of subsidized tokens is a campaign. A year of it is a problem in your own filing. The second-order point is that in both reads OpenAI stopped because of its own finances. Anthropic didn't win the war. It ended because the side paying for it chose to stop. The playbook still exists and it ran for a full quarter. It can be turned back on. That's the risk that remains. OpenAI restarts it. Or a rival like $SPCX xAI ships a next-gen model and discounts tokens hard to buy share. It's a bit like Uber's cash burn: a well-funded player can keep subsidizing longer than a margin-focused company wants to wait. I don't think that's fully priced in.

Investor Letters

All letters

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

MO $130B
Invariant 3 clicks

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $404M
The Oak Bloke 3 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 5 clicks

Microsoft's AI Boom Has A Cost

Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…

MSFT $4T
Yiannis Zourmpanos 2 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 4 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 275

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.